Anxiety and stress can trigger functional gastrointestinal disorders, whereas gastrointestinal symptoms can significantly increase anxiety and depression levels. These patterns are associated with the connection of the intestine and the brain through the “gut-brain axis,” a bi-directional communication of the nervous, endocrine, and immune systems. This clinical trial sought to investigate the effects of a novel nutraceutical supplement (Relaxigen Pet dog) containing natural anti-inflammatory compounds (CLA, Krill), pre/probiotics, 5-HTP, and L-theanine on stress-related behavior and to assess the connection between these stress-related behaviors and the fecal microbiome in dogs. Forty dogs, ranging in ages from 1 to 10 years, took part in this double-blind, placebo-controlled clinical trial. Ten dogs were control dogs without overt clinical signs of anxiety. Thirty dogs (experimental dogs) with signs of stress and anxiety were randomly assigned to the treatment (N = 20) and placebo (N = 10) groups. The treatment sample group (20 dogs balanced for sex) was administered with Relaxigen Pet dog tablets and the placebo group (10 dogs balanced for sex) with placebo tablets by mouth once a day for 60 days. A basic history questionnaire that focused on all aspects of dog's behavior, management, health issues, and behavioral signs of stress and anxiety, was collected at days 0, 30, and 60 for each experimental dog. A fecal sample was collected for all dogs at day 0 to compare the microbiome of the anxious and non-anxious dogs. The anxious dogs in the treatment and placebo dogs groups had a fecal sample collected again at 30 and 60 days. These samples were used to extract the DNA for microbiological analysis and to determine the leading bacterial group. ANOVA showed an influence of treatment × time and the group that received the treatment had a probability of improving greater than 10% (P ≤ 0.05). This study revealed a different structure of the intestinal microbiota between healthy dogs and those with stress-related behaviors at baseline. Supplementation with the Relaxigen seems to bring some changes in bacterial groups concentration in the treatment group of anxious dogs compared to the placebo one, but we must be very cautious in presenting these results due to the limitations of this pilot study (number of subjects, no dietary control, and no evaluation of microbiota over time for the control group dogs).

Effect of a novel nutraceutical supplement (Relaxigen Pet dog) on the fecal microbiome and stress-related behaviors in dogs: A pilot study / S. Cannas, B. Tonini, B. Belà, R. Di Prinzio, G. Pignataro, D. Di Simone, A. Gramenzi. - In: JOURNAL OF VETERINARY BEHAVIOR. - ISSN 1558-7878. - 42(2021 Mar 01), pp. 37-47. [10.1016/j.jveb.2020.09.002]

Effect of a novel nutraceutical supplement (Relaxigen Pet dog) on the fecal microbiome and stress-related behaviors in dogs: A pilot study

S. Cannas
Primo
;
B. Tonini
Secondo
;
2021

Abstract

Anxiety and stress can trigger functional gastrointestinal disorders, whereas gastrointestinal symptoms can significantly increase anxiety and depression levels. These patterns are associated with the connection of the intestine and the brain through the “gut-brain axis,” a bi-directional communication of the nervous, endocrine, and immune systems. This clinical trial sought to investigate the effects of a novel nutraceutical supplement (Relaxigen Pet dog) containing natural anti-inflammatory compounds (CLA, Krill), pre/probiotics, 5-HTP, and L-theanine on stress-related behavior and to assess the connection between these stress-related behaviors and the fecal microbiome in dogs. Forty dogs, ranging in ages from 1 to 10 years, took part in this double-blind, placebo-controlled clinical trial. Ten dogs were control dogs without overt clinical signs of anxiety. Thirty dogs (experimental dogs) with signs of stress and anxiety were randomly assigned to the treatment (N = 20) and placebo (N = 10) groups. The treatment sample group (20 dogs balanced for sex) was administered with Relaxigen Pet dog tablets and the placebo group (10 dogs balanced for sex) with placebo tablets by mouth once a day for 60 days. A basic history questionnaire that focused on all aspects of dog's behavior, management, health issues, and behavioral signs of stress and anxiety, was collected at days 0, 30, and 60 for each experimental dog. A fecal sample was collected for all dogs at day 0 to compare the microbiome of the anxious and non-anxious dogs. The anxious dogs in the treatment and placebo dogs groups had a fecal sample collected again at 30 and 60 days. These samples were used to extract the DNA for microbiological analysis and to determine the leading bacterial group. ANOVA showed an influence of treatment × time and the group that received the treatment had a probability of improving greater than 10% (P ≤ 0.05). This study revealed a different structure of the intestinal microbiota between healthy dogs and those with stress-related behaviors at baseline. Supplementation with the Relaxigen seems to bring some changes in bacterial groups concentration in the treatment group of anxious dogs compared to the placebo one, but we must be very cautious in presenting these results due to the limitations of this pilot study (number of subjects, no dietary control, and no evaluation of microbiota over time for the control group dogs).
Gutebrain axis; Fecal microbiome; Stress-related behavior; Dogs
Settore AGR/19 - Zootecnica Speciale
Settore AGR/18 - Nutrizione e Alimentazione Animale
1-mar-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Manuscript .pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 418.38 kB
Formato Adobe PDF
418.38 kB Adobe PDF Visualizza/Apri
1-s2.0-S1558787820301544-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 898.97 kB
Formato Adobe PDF
898.97 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/812321
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact